<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03381625</url>
  </required_header>
  <id_info>
    <org_study_id>BMX-DERM-01</org_study_id>
    <nct_id>NCT03381625</nct_id>
  </id_info>
  <brief_title>Topical Application of BMX-010 in Subjects With Atopic Dermatitis and Plaque Psoriasis</brief_title>
  <official_title>A Randomized, Placebo-Controlled, Dose-Escalation Trial to Evaluate the Safety, Clinical Effects, and Systemic Exposure of a Topical Application of BMX-010 in Subjects With Atopic Dermatitis and Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioMimetix JV, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioMimetix JV, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, placebo-controlled Phase 2 trial consisting of up to 300 subjects with
      either psoriasis or atopic dermatitis. In this trial BMX-010 will be topically applied twice
      daily for up to 28 days.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, randomized, multicenter, placebo-controlled study sponsored by BioMimetix
      JV, LLC (BMX). It is a double-blind parallel cohort study designed to determine the safety
      and efficacy of BMX-010 (0.03%) relative to Placebo in subjects with atopic dermatitis and
      psoriasis.

      Subjects will be queried regarding adverse events (AEs) and concomitant medication usage.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2, 2018</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Systemic Adverse Events Caused by BMX-010 on Atopic Dermatitis Lesions</measure>
    <time_frame>7-28 days</time_frame>
    <description>Assessment of adverse events occurring following topical administration of BMX-010 to atopic dermatitis lesions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Systemic Adverse Events Caused by BMX-010 on Psoriasis Lesions</measure>
    <time_frame>7-28 days</time_frame>
    <description>Assessment of adverse events occurring following topical administration of BMX-010 to psoriasis lesions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of BMX-010 against Placebo on Atopic Dermatitis and Psoriasis Lesions</measure>
    <time_frame>7-28 days</time_frame>
    <description>Assessment of efficacy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentrations (Cmax) for BMX-010</measure>
    <time_frame>8 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve (AUC) for BMX-010</measure>
    <time_frame>8 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Psoriasis</condition>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>BMX-010 0.03%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 subjects will receive BMX-010 0.03% twice daily for 7-28 days applied to psoriasis or atopic dermatitis lesions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>100 subjects will receive placebo twice daily for 7-28 days applied to psoriasis or atopic dermatitis lesions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMX-010</intervention_name>
    <description>Safety and efficacy of BMX-010 in topical treatment of psoriasis and/or atopic dermatitis.</description>
    <arm_group_label>BMX-010 0.03%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Topical administration of placebo in patients with psoriasis and/or atopic dermatitis.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of either atopic dermatitis or psoriasis with mild to moderate lesions
             involving 1% - 25% of total body surface area

          -  Candidate for topical treatment of atopic dermatitis or psoriasis

          -  Negative pregnancy test for females of childbearing potential

        Exclusion Criteria:

          -  Systemic pharmacotherapy or phototherapy for treatment of atopic dermatitis or
             psoriasis

          -  Erythrodermic, guttate or generalized pustular psoriasis

          -  Treatment of systemic retinoids, corticosteroids or immunosuppressive agents within 4
             weeks of baseline visit

          -  Treatment with high potency topical steroids, vitamin D analogs, keratolytics, coal
             tar, phototherapy, calcineurin inhibitors, or antihistamines within 2 weeks of
             baseline visit

          -  UV or Dead Sea therapy within 4 weeks of baseline visit

          -  Treatment with a biologic agent (monoclonal antibody) within 30 days or 5 times its
             circulating half-life (whichever is longer) prior to baseline visit

          -  Atopic dermatitis triggered by environmental allergen or irritant

          -  Contact dermatitis or drug-induced skin reactions

          -  Systemic or skin infection requiring antimicrobial therapy

          -  Systemic chemotherapy or radiotherapy within 4 weeks of baseline visit

          -  Immunocompromise of any cause

          -  Pregnancy, lactation or inadequate contraception

          -  Active drug or alcohol dependence

          -  Significant acute or chronic medical, neurological or psychiatric illness that would
             compromise subject's safety
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James D. Crapo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>BioMimetix JV, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>James D Crapo, MD</last_name>
    <phone>303-808-7314</phone>
    <email>james.crapo@BMXPharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elizabeth A. Regan, MD, PhD</last_name>
    <phone>303-921-1880</phone>
    <email>elizabeth.regan@BMXPharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Apex Dermatology</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra Theriault, MD</last_name>
      <phone>303-261-1525</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Colorado Skin Care</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly C Stone, MD</last_name>
      <phone>303-500-8667</phone>
    </contact>
    <investigator>
      <last_name>Kimberly C Stone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Juva Skin &amp; Laser Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Valerija Misev</last_name>
      <phone>212-688-5882</phone>
    </contact>
    <investigator>
      <last_name>Bruce Katz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2016</study_first_submitted>
  <study_first_submitted_qc>December 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 22, 2017</study_first_posted>
  <last_update_submitted>February 15, 2018</last_update_submitted>
  <last_update_submitted_qc>February 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

